Cannabinoids for Cancer Treatment: Progress and Promise

May 13, 2015 -

This experiment was carried out by Sami Sarfaraz, Vaqar M. Adhami, Deeba N. Syed, Farrukh Afaq, and Hasan Mukhtar at the Department of Dermatology, University of Wisconsin-Madison, Medical Sciences Center. It was published in the American Journal of Cancer and the Journal of Cancer Research in January 2008. They examined a ligation of CB2 receptors looking for new observable discoveries. Their findings showed that CB2 receptors of the immune system can be used for the induction of apoptosis (multicellular death). In the trial they applied a variety of different synthetic cannabinoids.

Cannabinoids are a class of pharmacologic compounds that offer potential applications as antitumor drugs, based on the ability of some members of this class to limit inflammation, cell proliferation, and cell survival. In particular, emerging evidence suggests that agonists of cannabinoid receptors expressed by tumor cells may offer a novel strategy to treat cancer. Here, we review recent work that raises interest in the development and exploration of potent, nontoxic, and nonhabit forming cannabinoids for cancer therapy.

To learn more about this clinical trial CLICK HERE.


If you would like to speak to us about how you can become involved with our foundation, become a sponsored family, or just need general information, please submit the form below and one of our team members will contact you promptly.